SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced additional topline results in a clinical study evaluating the potential of ZADAXIN® (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria™ from Novartis. According to investigators, ZADAXIN treatment given with the H1N1 vaccine led to a statistically significant (p value=0.04) increase in the percentage of subjects who seroconverted, also when evaluated 42 days after vaccination, compared to those who received the H1N1 vaccine alone…
Go here to see the original:
SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine
Popularity: unranked
Leave your response!